ARTICLE IN PRESS

Cytokine & Growth Factor Reviews xxx (2015) xxx-xxx

Contents lists available at ScienceDirect

Cytokine & Growth Factor Reviews

journal homepage: www.elsevier.com/locate/cytogfr



Survey

Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology

Heike M. Hermanns*

University Hospital Würzburg, Department of Internal Medicine II, Hepatology Research Laboratory, Grombühlstr. 12, 97080 Würzburg, Germany

ARTICLE INFO

Article history: Received 22 June 2015 Accepted 1 July 2015

Keywords:
Oncostatin M
Interleukin-31
Cytokines
Inflammation
Signal transduction

ABSTRACT

Oncostatin M (OSM) and interleukin-31 (IL-31) are two cytokines belonging to the IL-6 family which share a common signaling receptor subunit, the OSM receptor beta (OSMR β). Both of them are released by monocytes/macrophages, dendritic cells and T lymphocytes in inflammatory situations and upon binding to their respective receptor complexes they signal mainly via the JAK/STAT pathway. Besides sharing many biochemical properties, both display divergent physiological functions. This review summarizes aspects of cytokine transcription and biosynthesis, cytokine–receptor interactions, cross-species activities, signal transduction and physiology delineated from recent findings in genetic mouse models for both cytokines, OSM and IL-31.

© 2015 Published by Elsevier Ltd.

Contents

| 1. | Onco | statin M (OSM) | 000 | |
|-------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------|-----|--|
| | 1.1. | Transcription, biosynthesis and secretion of OSM | 000 | |
| | 1.2. | OSM cytokine-receptor interaction | 000 | |
| 1.3. OSM-mediated signal transduction | | | | |
| 1.4. Negative regulation of OSM signaling | | | | |
| 1.5. Genetic models to evaluate the physiological function of OSM | | | | |
| | | 1.5.1. Role of OSM in hematopoiesis, adipogenesis and osteogenesis. | 000 | |
| | | 1.5.2. Role of OSM in heart remodeling upon acute and chronic injury | 000 | |
| 2. | Interl | eukin-31 (IL-31) | 000 | |
| | 2.1. | Transcription, biosynthesis and secretion of IL-31 | 000 | |
| | 2.2. | Cytokine-receptor interaction | 000 | |
| | 2.3. | IL-31 signal transduction | 000 | |
| | 2.4. | Animal models investigating IL-31 physiology and recent findings for IL-31 in human disease | 000 | |
| | 2.5. | Strategies to blocking IL-31 activities | 000 | |
| 3. | Closin | ng remarks | 000 | |
| | Ackno | owledgements | 000 | |
| | Refer | ences | 000 | |
| | | | | |

1. Oncostatin M (OSM)

Even though the discovery of OSM dates back 25 years [1], its physiology and involvement in disease development are still incompletely understood. Initially discovered as a cytokine released from U937 cells which has cytostatic activities on the

growth of melanoma cells, hence its name oncostatin M, it is now becoming clear that OSM has multiple functions in hematopoiesis, mesenchymal stem cell differentiation, liver regeneration, heart remodeling, nociception, inflammation and metabolism (Fig. 1).

1.1. Transcription, biosynthesis and secretion of OSM

Within the last two decades the orthologues of human (h), bovine (b), murine (m) and rat (r) OSM have been cloned [1-4]

 $http://dx.doi.org/10.1016/j.cytogfr.2015.07.006\\1359-6101/@~2015~Published~by~Elsevier~Ltd.$

Please cite this article in press as: Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev (2015), http://dx.doi.org/10.1016/j.cytogfr.2015.07.006

^{*} Tel.: +49 931 20140026; fax: +49 931 201640170. E-mail address: Hermanns_H@ukw.de

ARTICLE IN PRESS

H.M. Hermanns/Cytokine & Growth Factor Reviews xxx (2015) xxx-xxx




Fig. 1. Main producers, target tissues and activities of OSM. Summary of some described target tissues of OSM as well as an excerpt of its physiological and pathophysiological functions.

(Tables 1 and 2). With the number of sequenced genomes increasing, further sequences are available for many more species (https://www.ncbi.nlm.nih.gov/gene, ortholog_gene_5008[group]). The exon–intron structure of the gene encoding OSM is identical between species with three exons separated by two introns. Interestingly, in all species the *OSM/Osm* gene is located in direct proximity to the gene encoding leukemia inhibitory factor (LIF) which might indicate that both have originated from a gene duplication [5,6].

For human and murine OSM the promoters have been characterized and indicate that *OSM/OSm* transcription is controlled by C/EBP and GC-rich elements for basal activity, but that STAT5 response elements are crucial for stimulus-dependent increase in transcription. Transcriptional silencer(s) located between nt –194 and –109 in the proximal human *OSM* promoter appear to assure cell-specific control of OSM expression [3,7,8]. Indeed, stimulation of many hematopoietic cell types with cytokines activating STAT5, like IL-2, IL-3, EPO, GM-CSF, results in a strong expression of OSM. Not surprisingly, OSM was then identified as an amplifier of cytokine production and bone

marrow remodeling in myoproliferative neoplasms carrying oncogenic JAK2 mutations (TEL/JAK2 and JAK2-V617F) which result in constitutive activation of STAT5 [9,10]. Recently, a number of studies have shown that OSM transcription is upregulated in response to prostaglandin E2 in a cAMP-dependent manner [11–14]. Major cell types secreting OSM upon stimulation are activated monocytes/macrophages, neutrophils, dendritic cells and T-lymphocytes [15–20]. Furthermore, mOSM mRNA is present in the bone marrow to a much higher extent than in the spleen which points to a role of OSM in hematopoiesis and/or osteogenesis [3]. Hematopoietic cells in the bone marrow were identified as source of OSM [21]. Its expression is, however, undetectable in liver, lung, ovary, small intestine, kidney and brain [3,21].

The more than 1000 nt long 3' untranslated regions (3' UTR) of the human and murine OSM mRNAs contain several AU-rich sequences which are known to be involved in the regulation of mRNA stability of several cytokines including e.g. IL-6 [22] (reviewed in: [23]). Regarding the hOSM mRNA it was recently

Table 1Processing and posttranslational modifications (PTM) of OSM and IL-31 orthologues as well as topology and PTM of OSMRβ and IL-31RA orthologues (according to www. uniprot.org).

| Cytokine | Full-length protein | Signal peptide | C-terminal prodomain | Mature protein | Disulfide bonds | N-glycosylation sites (predicted) |
|----------------------------|---------------------|----------------|-------------------------|----------------|----------------------|-----------------------------------|
| hOSM | 252 aa | 25 aa | 32 aa | 195 aa | 2 | 2 |
| bOSM | 245 aa | 26 aa | 40 aa | 179 aa | 2 | 1 |
| rOSM | 239 aa | 25 aa | 32 aa | 182 aa | 2 | - |
| mOSM | 263 aa | 24 aa | 58 aa | 181 aa | 2 | 3 |
| hIL-31 | 164 aa | 23 aa | _ | 141 aa | 1 | 2 |
| mIL-31 | 163 aa | 23 aa | _ | 140 aa | 1 | 3 |
| Receptor | Full-length protein | Signal peptide | Extracellular region | TM domain | Intracellular region | N-glycosylation sites (predicted) |
| hOSMRβ | 979 aa | 27 aa | 713 aa | 21 aa | 218 aa | 5 |
| mOSMRβ | 971 aa | 23 aa | 714 aa | 21 aa | 213 aa | 14 |
| rOSMRβ | 962 aa | 28 aa | 710 aa | 21 aa | 203 aa | 5 |
| hIL-31RA (main isoform) | 732 aa | 19 aa | 500 aa | 21 aa | 192 aa | 10 |
| mIL-31RA | 716 aa | 18 aa | 481 aa | 21 aa | 196 aa | 4 |

Please cite this article in press as: Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev (2015), http://dx.doi.org/10.1016/j.cytogfr.2015.07.006

ว

Download English Version:

https://daneshyari.com/en/article/10930072

Download Persian Version:

https://daneshyari.com/article/10930072

<u>Daneshyari.com</u>